Results of quinacrine administration to patients with Creutzfeldt-Jakob disease
Results of quinacrine administration to patients with Creutzfeldt-Jakob disease
复制标题
DOI：
10.1159/000076350
复制
发表时间：
2004-01-01
影响因子：
2.4
通讯作者：
Kataoka, Y
中科院分区：
文献类型：
--
作者：
Nakajima, M;Yamada, T;Kataoka, Y
几种化学物质在体外抑制异常朊病毒蛋白的积累。我们管理一个，抗疟药奎纳克林，散发性克雅氏病（CJD）和医源性克雅氏病的三名患者。奎纳克林以300毫克/天肠内给药3个月。在给药2周内，运动不能性缄默症患者的觉醒水平得到改善。另外3例患者在治疗前无感觉，恢复了对语言和/或视觉刺激的整合反应，如目光接触或自愿运动。临床改善是短暂的，在治疗期间持续1 - 2个月。除肝功能障碍和黄色色素沉着外，奎纳克林耐受性良好。尽管奎纳克林在人脑中的抗朊病毒活性尚未得到证实，但其温和的作用表明，有可能使用化学干预来对抗朊病毒疾病。版权所有（C）2004 S. Karger AG，巴塞尔。
Several chemicals inhibit the accumulation of abnormal prion proteins in vitro. We administered one, the antimalarial agent quinacrine, to three patients with sporadic Creutzfeldt-Jakob disease (CJD) and to one with iatrogenic CJD. Quinacrine at 300 mg/day was given enterally for 3 months. Within 2 weeks of administration, the arousal level of the patient with akinetic mutism improved. The other 3 patients, insensible before treatment, had integrative responses such as eye contact or voluntary movement in response to verbal and/or visual stimuli restored. Clinical improvement was transient, lasting 1 - 2 months during treatment. Quinacrine was well tolerated, except for liver dysfunction and yellowish pigmentation. Although its antiprion activity in the human brain has yet to be proved, these modest effects of quinacrine suggest the possibility of using chemical intervention against prion diseases. Copyright (C) 2004 S. Karger AG, Basel.